MAIRE-TECNIMONT
21.7.2020 10:02:08 CEST | Business Wire | Press release
Maire Tecnimont Group, the Italian engineering multinational, is bringing legal action in the High Court in London against NatWest, following the bank’s failure to stop it falling victim to a “push-payment” fraud.
In 2018, Maire Tecnimont’s subsidiary in Saudi Arabia was duped (via an internal email account hacked by unidentified criminal elements) into sending $5 million to a bank account held with NatWest.
Despite this account having seen very little activity in the preceding period, and none involving such large sums, NatWest did not freeze the account pending further investigation. The controller of the NatWest account then appears to have almost immediately dispersed the stolen money in a flurry of numerous large payments to bank accounts in several different countries. NatWest allowed these payments to take place, despite the fact that they prompted two internal fraud alerts at the UK bank. Maire Tecnimont’s legal action claims this was a breach of the bank’s obligations under UK regulations against money laundering and terrorist financing. The funds paid out of the NatWest account became untraceable, for all practical purposes. They have not been recovered and are presumed to have fallen into criminal hands.
Maire Tecnimont is suing for $3.76 million - the amount still left in the account when NatWest’s first fraud alarm was triggered - plus interest and costs. According to the claim, Natwest fell short of standards of commercially acceptable conduct for a bank in relation to the prevention of fraud, money laundering, terrorist financing and financial crime.
The legal action argues that banks have a responsibility to take appropriate steps to prevent the dissipation of stolen or laundered funds. It may create clarity in what is currently an uncertain area of English law by establishing whether banks are required to prevent all fraud perpetrated using their accounts, not just fraud against the bank’s own customers.
Robert Wynn Jones of Mishcon de Reya, legal representative of Maire Tecnimont, said:
“Maire Tecnimont confirms it is suing NatWest over its lamentable failure to prevent a push-payment fraud through which the company lost millions of dollars.
“It is unacceptable and, frankly, inexplicable that NatWest did not prevent this fraud. The sudden appearance of such a large sum of money originating overseas into an essentially dormant bank account should have rung alarm bells. The bank has heavy anti-money laundering and anti-terrorism obligations, to say nothing of its general responsibility to protect banking customers. All of these controls failed.
“NatWest is a systemically-important UK bank with millions of customers. If it doesn’t have adequate safeguards to protect people against this kind of confidence scam, that is concerning for everybody.”
The legal action has been filed by Tecnimont Arabia Limited, a subsidiary of Maire Tecnimont SpA, which is represented by Robert Wynn Jones and John Sendama of Mishcon de Reya LLP. The claim number is LM-2020-000077.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
